10q10k10q10k.net
aTYR PHARMA INC

aTYR PHARMA INCATYREarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024

ATYR Q4 FY2025 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

N/A

Net Profit

N/A

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

aTYR PHARMA INC Q4 FY2025 Financial Summary

aTYR PHARMA INC reported revenue of $0 for Q4 FY2025, with a net profit of N/A (up 6.7% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net ProfitN/A
Gross MarginN/A
Operating MarginN/A
Report PeriodQ4 FY2025

aTYR PHARMA INC Annual Revenue by Year

aTYR PHARMA INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $190.0K).

YearAnnual Revenue
2025$190.0Kvs 2024 →
2024$235.0Kvs 2023 →

aTYR PHARMA INC Quarterly Revenue & Net Profit History

aTYR PHARMA INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$0—N/AN/A
Q3 FY2025$190.0K—$-25.7M-13549.5%
Q2 FY2025$0—$-19.5MN/A
Q1 FY2025$0—$-14.9MN/A
Q4 FY2024$0—N/AN/A
Q3 FY2024$0—$-17.3MN/A
Q2 FY2024$0—$-16.3MN/A
Q1 FY2024$235.0K—$-15.5M-6591.9%

Income Statement

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$235000$0$0$0$0$0$190000$0
YoY GrowthN/AN/AN/AN/AN/AN/AN/AN/A

Balance Sheet

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$113.3M$105.9M$91.6M$96.8M$97.2M$101.5M$106.7M$93.0M
Liabilities$28.8M$24.3M$26.3M$26.8M$22.2M$26.7M$26.4M$25.5M
Equity$84.5M$81.6M$65.3M$70.0M$75.0M$74.8M$80.2M$67.5M

Cash Flow

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-22.4M$-20.4M$-13.2M$-69.1M$-15.4M$-13.9M$-20.5M$-62.0M